Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study

[1] Asch P(2011)Impact of mobility impairment in multiple sclerosis 2—patient perspectives Eur Neurol Rev. 6 115-120

[2] Panitch H(2011)Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability Expert Opin Pharmacother 12 1511-1521

[3] Applebee A(2008)Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable Mult Scler 14 988-991

[4] Heesen C(2010)Contribution of impaired mobility to patient burden in multiple sclerosis Curr Med Res Opin 26 109-119

[5] Bohm J(2010)A phase 3 trial of extended release oral dalfampridine in multiple sclerosis Ann Neurol 68 494-502

[6] Reich C(2019)Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine CNS Drugs 33 61-79

[7] Kasper J(2016)Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial Mult Scler 22 212-221

[8] Goebel M(2018)Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria? Mult Scler 24 1337-1346

[9] Gold SM(2001)The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure Brain 124 962-973

[10] Sutliff MH(2015)Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life J Neurol 262 1936-1945

[1] Asch P(2011)Impact of mobility impairment in multiple sclerosis 2—patient perspectives Eur Neurol Rev. 6 115-120

[2] Panitch H(2011)Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability Expert Opin Pharmacother 12 1511-1521

[3] Applebee A(2008)Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable Mult Scler 14 988-991

[4] Heesen C(2010)Contribution of impaired mobility to patient burden in multiple sclerosis Curr Med Res Opin 26 109-119

[5] Bohm J(2010)A phase 3 trial of extended release oral dalfampridine in multiple sclerosis Ann Neurol 68 494-502

[6] Reich C(2019)Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III ENHANCE trial of prolonged-release fampridine CNS Drugs 33 61-79

[7] Kasper J(2016)Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial Mult Scler 22 212-221

[8] Goebel M(2018)Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria? Mult Scler 24 1337-1346

[9] Gold SM(2001)The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure Brain 124 962-973

[10] Sutliff MH(2015)Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life J Neurol 262 1936-1945